Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 122

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 122
---
 paid in respect of such liabilities. The Selling Shareholder has agreed to indemnify us against liabilities under the Securities
Act that may arise from certain written information furnished to us by the Selling Shareholder specifically for use in this prospectus
or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised
that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.

We estimate that the total
expenses, including the Commitment Fee, for the offering will be approximately $1.7 million.

The Selling Shareholder has
represented to us that at no time prior to the date of the Purchase Agreement has the Selling Shareholder or its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule
200 of Regulation SHO of the Exchange Act) of our Depositary Shares or any hedging transaction, which establishes a net short position
with respect to our Depositary Shares. The Selling Shareholder has agreed that during the term of the Purchase Agreement, neither the
Selling Shareholder, nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the
foregoing transactions.

We have advised the Selling
Shareholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M
precludes the Selling Shareholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution
from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a
security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered
by this prospectus.

This offering will terminate
on the date that all of our Depositary Shares offered by this prospectus have been sold by the Selling Shareholder.

Our Depositary Shares are
currently listed on The NASDAQ Capital Market under the symbol “BDRX.”

<div align='center'>EXPENSES OF THE OFFERING</div>

The following table sets
forth the